U.S. Government Organizations Release Positive Information About VIVITROL (CEPH) for the Treatment of Alcoholism

May 15, 2007 1:20 PM EDT

The Substance Abuse and Mental Health Services Administration (SAMHSA), a public health agency within the U.S. Department of Health and Human Services, issued its quarterly Substance Abuse Treatment Advisory developed for the education of healthcare professionals in the field of substance abuse. The advisory features a comprehensive overview of VIVITROL® (naltrexone for extended- release injectable suspension), the first and only once-monthly injectable medication for the treatment of alcohol dependence, which was approved by the FDA in April 2006.

This advisory follows the publication of an updated version of Helping Patients Who Drink Too Much: A Clinician's Guide from the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The Guide was recently updated to include information about VIVITROL as the most recently FDA-approved medication for the treatment of alcohol dependence.

"We are pleased that these government organizations have formally recognized VIVITROL, the first and only once-monthly injectable medication for the treatment of alcohol dependence, as an important and effective treatment option in their recent publications," said David Gastfriend, MD, Vice President, Medical Affairs at Alkermes (Nasdaq: ALKS). "We encourage healthcare providers, including addiction specialists and primary care doctors, to utilize this valuable information as they evaluate and treat their patients who struggle with the deadly disease of alcoholism."

VIVITROL® is a registered trademark of Cephalon, Inc (Nasdaq: CEPH), Medisorb is a registered trademark of Alkermes, Inc. (Nasdaq: ALKS)

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?